Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA-1: APT-001 in Blepharitis
NCT06720896Phase 2Completed
- Sponsor
- Aperta Biosciences
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
A Phase 2 trial of spinosad in blepharitis, sponsored by Aperta Biosciences. Started Nov 2025; status: completed.
02
Drugs
spinosad
03
Conditions
blepharitis
Beyond the preview
Go deeper on NCT06720896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720896.